NASDAQ: EVOKEvoke Pharma Inc Stock
$2.69+0.05 (+1.89%)
Updated Apr 29, 2025
EVOK Price
$2.69
Fair Value Price
N/A
Market Cap
$4.02M
52 Week Low
$1.94
52 Week High
$12.32
P/E
-0.96x
P/B
0.57x
P/S
0.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.25M
Earnings
-$5.35M
Gross Margin
96.5%
Operating Margin
-47.33%
Profit Margin
-52.2%
Debt to Equity
1.49
Operating Cash Flow
-$5M
Beta
0.4
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
EVOK Overview
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EVOK's potential to beat the market
- EVOK doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
EVOK
RankedUnranked of 58
RankedUnranked of 58
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.75 | A | |
| $32.49 | A | |
| $27.00 | A |
Be the first to know about important EVOK news, forecast changes, insider trades & much more!
EVOK News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EVOK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EVOK is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EVOK is good value based on its book value relative to its share price (0.57x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.09x)
P/B vs Industry Valuation
EVOK is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EVOK due diligence checks available for Premium users.
Valuation
EVOK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.96x
Industry
21.8x
Market
29.19x
EVOK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.57x
Industry
2.09x
EVOK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EVOK's financial health
Profit margin
Revenue
$3.3M
Net Income
-$1.2M
Profit Margin
-36.1%
EVOK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
EVOK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$17.5M
Liabilities
$10.5M
Debt to equity
1.49
EVOK's short-term assets ($17.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVOK's short-term assets ($17.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVOK's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EVOK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
$0.0
Financing
$3.5M
EVOK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EVOK vs Pharmaceutical Stocks
Evoke Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.